AGG Food & Drug Newsletter - December 2019

Arnall Golden Gregory LLP
Contact

Arnall Golden Gregory LLP's Food and Drug Newsletter is a monthly update of legal and regulatory issues that affect the FDA-regulated community, including regular updates on legislative initiatives from AGG’s Washington, DC office, and articles from members of AGG outside the Food and Drug Practice.

Industry Insights


“A Perfect Storm”: OPDP Sends Warning Letter Regarding Print Advertisement for Drug to Treat Opioid Use Disorder—Failure to Disclose Serious Risks, Including Potential for Fatal Overdose
By: Seth S. Ray

On December 2, 2019, the Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) sent a Warning Letter to the sponsor of a drug that is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. According to OPDP, the sponsor’s print advertisement was false or misleading, because it omitted important risk information associated with the use of the drug. The print ad failed to disclose the potential for fatal overdose in this vulnerable patient population, and, as OPDP noted, opioid dependence and misuse is a significant public health concern and national crisis affecting millions of people. More >

Is Your Cosmetic Product Really Natural? Congress Pushes for Legislation to Define the Term “Natural” for Cosmetics
By: Carolina M. Wirth

The use of the term “natural” on the labeling of FDA-regulated products has been the source of many lawsuits in recent years, and even the subject of enforcement actions by the Federal Trade Commission (FTC). However, neither the FTC nor the FDA have established a definition for the term “natural.” More >

Understanding USP 800: A Resource for Long-Term Care Providers
By: Jennifer L. Hilliard and Robert Durkin

When many long-term care providers first hear about USP General Chapter <800> Hazardous Drugs–Handling in Healthcare Settings (“USP 800”), they naturally confuse it with the final EPA hazardous pharmaceuticals rule (“EPA Rule”), which became effective in August 2019. While there certainly are areas in which the two overlap, the provisions of the EPA Rule concern hazardous pharmaceuticals once they are no longer used for their intended purpose and thus become waste. USP 800, however, concerns hazardous drugs (“HDs”) throughout their entire post-manufacturing lifecycle—from receiving and storage through disposal. As such, USP 800 is likely to have a profound effect on pharmacy and health care facility operations. More >

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Arnall Golden Gregory LLP | Attorney Advertising

Written by:

Arnall Golden Gregory LLP
Contact
more
less

Arnall Golden Gregory LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide